| Literature DB >> 34204481 |
Maria Lopez Chiloeches1, Anna Bergonzini1, Teresa Frisan1.
Abstract
The idea that bacterial toxins are not only killers but also execute more sophisticated roles during bacteria-host interactions by acting as negotiators has been highlighted in the past decades. Depending on the toxin, its cellular target and mode of action, the final regulatory outcome can be different. In this review, we have focused on two families of bacterial toxins: genotoxins and pore-forming toxins, which have different modes of action but share the ability to modulate the host's immune responses, independently of their capacity to directly kill immune cells. We have addressed their immuno-suppressive effects with the perspective that these may help bacteria to avoid clearance by the host's immune response and, concomitantly, limit detrimental immunopathology. These are optimal conditions for the establishment of a persistent infection, eventually promoting asymptomatic carriers. This immunomodulatory effect can be achieved with different strategies such as suppression of pro-inflammatory cytokines, re-polarization of the immune response from a pro-inflammatory to a tolerogenic state, and bacterial fitness modulation to favour tissue colonization while preventing bacteraemia. An imbalance in each of those effects can lead to disease due to either uncontrolled bacterial proliferation/invasion, immunopathology, or both.Entities:
Keywords: bacterial genotoxins; cytokines; immunoregulation; innate and adaptive immunity; polarization immune response; pore-forming toxins
Mesh:
Substances:
Year: 2021 PMID: 34204481 PMCID: PMC8235270 DOI: 10.3390/toxins13060426
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Toxins’ contributions to persistent or acute pathological bacterial conditions. Bacterial genotoxins (BTGXs) and pore-forming toxins (PFTs) can contribute to the modulation of the host’s immune response (IR) during bacterial infection (BI). When BTGXs and PFTs contribute to avoid complete bacterial clearance by the IR and limit immunopathology, the infection can persist for long time, eventually asymptomatically (where chronic carrier status can be associated with pathologies such as cancer). However, when this delicate equilibrium is broken, due to high toxin- and bacterial-induced tissue damage or uncontrolled immune responses, pathological conditions develop.
Bacterial genotoxins.
| Bacterium | Toxin |
|---|---|
|
| AaCDT |
|
| CjCDT |
|
| EcCDT |
|
| Colibactin ( |
|
| HdCDT |
|
| HcCDT |
|
| HhCDT |
|
| HpCDT |
|
| HsCDT |
|
| Typhoid toxin (TT) |
Pore-forming toxins.
| Bacterium | Toxin | Acronym |
|---|---|---|
|
| Aerolysin | |
|
| Perfringolysin | PFO |
|
| Hemolysin | HlyA |
|
| Cytolysin | ClyA |
| Group A | Streptolysin | SLO |
| Group B | Hemolysin/cytolysin | bh/c |
|
| Vacuolating toxin A | VacA |
|
| Lysteriolysin O | LLO |
|
| α-Toxin | |
|
| Pneumolysin | PLY |
|
| Suilysin | SLY |
Figure 2Bacterial genotoxins (BTGXs) and pore-forming toxins (PFTs) have different modes of action on the target cells but share common pathways and outcomes as immunomodulators resulting in either: (i) secretion of pro-inflammatory cytokines (key regulatory effectors described in the text are highlighted in red; left panel); (ii) suppression/degradation of pro-inflammatory cytokines and/or secretion of anti-inflammatory mediators (key regulatory effectors described in the text are highlighted in green; right panel). AP1: Activator Protein 1 (transcription factor); ATM: ataxia telangiectasia mutated (kinase); IRFs: interferon-responsive factors (transcription factors); MAPKs: mitogen-activated protein kinases; NFAT: nuclear factor of activated T cells (transcription factor); NFκB: nuclear factor-kB (transcription factor); SOCS1: suppressor of cytokine signalling 1; Ub: ubiquitin.
Figure 3Different immunosuppressive effects of BTGXs and PFTs. BTGXs and PFTS can modulate the host’s immune response by several non-mutually exclusive mechanisms: (a) suppression of pro-inflammatory cytokine production/secretion (PFT); (b) re-polarization of the host’s immune response from a pro-inflammatory (Th1 and Th17) to a tolerogenic and tissue repair-prone response (Th2); and (c) toxin expression can reduce the fitness of the bacterium to survive hostile environments such as the blood, favouring tissue colonization and preventing bacteraemia. This can lead to a balance between bacterial infection/colonization (BI) and uncontrolled activation of the immune response (IR).